When Bioprosthetic Mitral Valves Fail: Redo Surgery Bests Transcatheter Treatment After 5 Years

Why It Matters

The findings shift the risk‑benefit calculus toward surgery for eligible patients, reinforcing guideline recommendations and influencing heart‑team decision making.

Key Takeaways

• Redo SMVR 5‑year mortality 20.3%, half of mViV.
• mViV offers shorter hospital stays but higher long‑term death.
• Mitral gradients lower after surgical redo than transcatheter.
• Reintervention rates similar between surgery and valve‑in‑valve.
• Guidelines favor surgery for low‑risk patients with longer life expectancy.

Pulse Analysis

Bioprosthetic mitral valves are increasingly used because they avoid long‑term anticoagulation, yet structural degeneration remains inevitable after 10‑15 years. When failure occurs, clinicians must choose between a repeat open‑heart operation and a less invasive transcatheter mitral valve‑in‑valve (mViV) procedure. The decision hinges on patient age, comorbidities, and expected durability, making robust comparative data essential for heart‑team discussions.

The multicenter cohort examined 229 patients treated between 2004 and 2023, with 90 undergoing redo SMVR and 139 receiving mViV. Although both groups showed similar 30‑day mortality and mViV patients left the hospital sooner, the five‑year all‑cause mortality diverged sharply—20.3 % for surgery versus 40.9 % for the transcatheter approach. Additionally, postoperative mitral gradients were markedly lower after redo surgery, indicating better hemodynamic performance, while freedom from reintervention remained comparable across techniques.

These results reinforce existing guideline language that recommends redo SMVR for low‑risk individuals with longer life expectancy. As transcatheter technology continues to evolve, future studies will need to assess whether newer devices can close the survival gap. Meanwhile, surgeons and interventional cardiologists must weigh short‑term convenience against long‑term durability, especially as the aging population drives demand for durable valve solutions.